Drug
GLPG-3970 clinical trials
Also written GLPG3970.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
8 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GLPG-3970 is read from its arms, and is right about nine times in ten.
Testing it · 8
- Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy SubjectsCompletedPhase 1Galapagos NVNCT04720183Written as GLPG3970
- A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970CompletedPhase 1Lakefront Biotherapeutics NVNCT04106297Written as GLPG3970 oral solution
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)TerminatedPhase 2Galapagos NVNCT04700280Written as GLPG3970
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative ColitisCompletedPhase 2Galapagos NVNCT04577794Written as GLPG3970
- A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedPhase 2Galapagos NVNCT04577781Written as GLPG3970
- A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus ErythematosusTerminatedPhase 1Galapagos NVNCT04700267Written as GLPG3970 film-coated tablet
- Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970CompletedPhase 1Galapagos NVNCT04907149Written as GLPG3970 film-coated tablet
- A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970CompletedPhase 1Galapagos NVNCT04708184Written as GLPG3970 oral solution